Literature DB >> 15987294

Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.

A Wojas-Pelc1, M Błaszczyk, M Glińska, S Jabłońska.   

Abstract

We present an unusual tumorous variety of scleromyxedema mimicking facies leonina in lymphoma. In spite of pronounced and widespread cutaneous changes, hypergammaglobulinaemia and paraproteinaemia, the general condition of the patient was satisfactory, there was no internal involvement and no symptoms of any malignancy. Initially, melphalan and corticosteroids were applied but were not effective. High-dose intravenous immunoglobulin (IVIG) therapy had dramatic effect, and after five 5-day monthly courses the tumours almost regressed and the skin became less hard. After a further five courses in the following year there was complete clearance, which was sustained without any therapy for 1 year (until now). IVIG appears to be the therapy of choice for scleromyxedema. We stress, however, that at the start of therapy, IVIG applications should be supplemented with small doses of melphalan and/or corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987294     DOI: 10.1111/j.1468-3083.2005.01134.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 2.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 3.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

4.  Scleromyxedema: clinical diagnosis and autopsy findings.

Authors:  Ana Carolina Bulhões Sala; Paulo Rowilson Cunha; Clóvis Antônio Lopes Pinto; Célia Antônia Xavier de Moraes Alves; Ingrid Barreto Paiva; Ana Paula Vieira Araujo
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

5.  Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin.

Authors:  M Dolenc-Voljč; V Jurčić; A Hočevar; M Tomšič
Journal:  Case Rep Dermatol       Date:  2013-11-02

6.  Scleromyxedema: a rare disorder and its treatment difficulties.

Authors:  Sandra Koleta Koronowska; Agnieszka Osmola-Mańkowska; Oliwia Jakubowicz; Ryszard Zaba
Journal:  Postepy Dermatol Alergol       Date:  2013-04-12       Impact factor: 1.837

7.  Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report.

Authors:  Federica Arginelli; Franco Rongioletti; Giampiero Girolomoni; Giovanni Pellacani; Davide Guardoli; Andrea Conti
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.